Everything above comes from Kairos Pharma, Ltd.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Share-count jumps we cannot explain: 1.62x around Dec 31, 2025. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.

Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, Profit Before Tax, Interest Expense, Income Tax Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Receivables, Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (current), Operating Lease (noncurrent), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Capital Expenditures, Investing Cash Flow, Dividends paid, Impairments, Stock-Based Compensation, Depreciation, Share Repurchases, Change in Inventories, Change in Receivables, Change in Payables, Change in Payables and Accruals, Change in Customer Advances, Change in Other Operating Capital, Change in Working Capital, Accounts Payable, Acquisitions, and Shares Issued for Cash. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.